University of Texas Medical Branch
Galveston, Texas, 77555, United States
Location status: Recruiting
Location contact
Cindy Mitchell, CCRC
CONTACT
Lisa Sweeney, RN
CONTACT
William J. Calhoun, M.D
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05331170
This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Phase 2
Galveston, Texas, 77555, United States
Location status: Recruiting
Cindy Mitchell, CCRC
CONTACT
Lisa Sweeney, RN
CONTACT
William J. Calhoun, M.D
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy Normal Control Group
Allergic Rhinitis Group
Allergic Asthma Group
Inclusion criteria
Exclusion criteria
Healthy Group Normal Group
Allergic Rhinitis Group
Allergic Asthma Group
Exploration of the effects of RV inoculation on human airway mucosal programming in vivo
Time frame: Immediate
Q-PCR
Time frame: Immediate
Q-RT-PCR
Time frame: Immediate
Q-RT-PCR
Time frame: 48 hours after inoculation
Plaque Assays
Time frame: Immediate and 48hrs post RV16 inoculation
Proportion and number of CD8+ T cells
Time frame: Immediate and 48 hrs post RV16 inoculation
Lamina reticularis thickness
Time frame: Immediate and up to 7 days following inoculation
WURSS21 Questionnaire
Contact information is provided by the study sponsor or research team.
The University of Texas Medical Branch, Galveston
Other
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING
Acronym: VMR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03509766
Allergic Rhinitis, Asthma
Baltimore, Maryland, United States
View Trial DetailsNCT03599908
Allergic Rhinitis, Asthma
View Trial DetailsNCT05476484
Allergic Rhinitis, Allergy
Hørsholm, Copenhagen, Denmark
View Trial DetailsNCT02831348
Allergic Rhinitis, Asthma
Boston, Massachusetts, United States
View Trial Details